Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

CTLA-4Ig blocks the development and progression of citrullinated fibrinogen-induced arthritis in DR4-transgenic mice.

Yue D, Brintnell W, Mannik LA, Christie DA, Haeryfar SM, Madrenas J, Chakrabarti S, Bell DA, Cairns E.

Arthritis Rheum. 2010 Oct;62(10):2941-52. doi: 10.1002/art.27597.

2.

T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization.

Koenders MI, Marijnissen RJ, Joosten LA, Abdollahi-Roodsaz S, Di Padova FE, van de Loo FA, Dulos J, van den Berg WB, Boots AM.

Arthritis Rheum. 2012 Jun;64(6):1762-70. doi: 10.1002/art.34352. Epub 2011 Dec 27.

3.
4.

Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice.

Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, Lee DM, Hueber W, Robinson WH, Cairns E.

J Exp Med. 2008 Apr 14;205(4):967-79. doi: 10.1084/jem.20072051. Epub 2008 Apr 7.

5.

Preventing and curing citrulline-induced autoimmune arthritis in a humanized mouse model using a Th2-polarizing iNKT cell agonist.

Walker KM, Rytelewski M, Mazzuca DM, Meilleur SA, Mannik LA, Yue D, Brintnell WC, Welch I, Cairns E, Haeryfar SM.

Immunol Cell Biol. 2012 Jul;90(6):630-9. doi: 10.1038/icb.2011.78. Epub 2011 Sep 13.

PMID:
21912419
6.

Immunization with Porphyromonas gingivalis enolase induces autoimmunity to mammalian α-enolase and arthritis in DR4-IE-transgenic mice.

Kinloch AJ, Alzabin S, Brintnell W, Wilson E, Barra L, Wegner N, Bell DA, Cairns E, Venables PJ.

Arthritis Rheum. 2011 Dec;63(12):3818-23. doi: 10.1002/art.30639.

7.

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.

Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC.

Arthritis Rheum. 2002 Jun;46(6):1470-9.

8.

Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis.

Bonelli M, Göschl L, Blüml S, Karonitsch T, Hirahara K, Ferner E, Steiner CW, Steiner G, Smolen JS, Scheinecker C.

Rheumatology (Oxford). 2016 Apr;55(4):710-20. doi: 10.1093/rheumatology/kev403. Epub 2015 Dec 16.

9.

Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints.

Angyal A, Egelston C, Kobezda T, Olasz K, László A, Glant TT, Mikecz K.

Arthritis Res Ther. 2010;12(2):R44. doi: 10.1186/ar2954. Epub 2010 Mar 18.

10.

CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells.

Remans PH, Wijbrandts CA, Sanders ME, Toes RE, Breedveld FC, Tak PP, van Laar JM, Reedquist KA.

Arthritis Rheum. 2006 Oct;54(10):3135-43.

11.

Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis.

Bonelli M, Ferner E, Göschl L, Blüml S, Hladik A, Karonitsch T, Kiener HP, Byrne R, Niederreiter B, Steiner CW, Rath E, Bergmann M, Smolen JS, Scheinecker C.

Arthritis Rheum. 2013 Mar;65(3):599-607. doi: 10.1002/art.37787.

12.

The role of citrullination of an immunodominant proteoglycan (PG) aggrecan T cell epitope in BALB/c mice with PG-induced arthritis.

Misják P, Bősze S, Horváti K, Pásztói M, Pálóczi K, Holub MC, Szakács F, Aradi B, György B, Szabó TG, Nagy G, Glant TT, Mikecz K, Falus A, Buzás EI.

Immunol Lett. 2013 Apr;152(1):25-31. doi: 10.1016/j.imlet.2013.03.005. Epub 2013 Apr 8.

PMID:
23578666
13.

Citrullinated mouse collagen administered to DBA/1J mice in the absence of adjuvant initiates arthritis.

Thiele GM, Duryee MJ, Dusad A, Hunter CD, Lacy JP, Anderson DR, Wang D, O'Dell JR, Mikuls TR, Klassen LW.

Int Immunopharmacol. 2012 Aug;13(4):424-31. doi: 10.1016/j.intimp.2012.05.007. Epub 2012 May 21.

PMID:
22626832
14.

Anti-ICAM-1 antibody and CTLA-4Ig synergistically enhance immature dendritic cells to induce donor-specific immune tolerance in vivo.

Wang Q, Zhang M, Ding G, Liu Y, Sun Y, Wang J, Zhang W, Fu Z, Cao X.

Immunol Lett. 2003 Nov 15;90(1):33-42.

PMID:
14611905
15.

CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model.

Roser-Page S, Vikulina T, Zayzafoon M, Weitzmann MN.

Arthritis Rheumatol. 2014 Apr;66(4):990-9. doi: 10.1002/art.38319.

16.
17.

Presence and role of anti-citrullinated protein antibodies in experimental arthritis models.

Cantaert T, Teitsma C, Tak PP, Baeten D.

Arthritis Rheum. 2013 Apr;65(4):939-48. doi: 10.1002/art.37839.

18.

The effect of CTLA-4Ig, a CD28/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis.

Jiménez-Alvarez L, Arreola JL, Ramírez-Martínez G, Ortiz-Quintero B, Gaxiola M, Reynoso-Robles R, Avila-Moreno F, Urrea F, Pardo A, Selman M, Zuñiga J.

Exp Mol Pathol. 2011 Dec;91(3):718-22. doi: 10.1016/j.yexmp.2011.09.010. Epub 2011 Sep 14.

PMID:
21945736
19.

[Inhibition by CTLA-4Ig on herpetic stromal keratitis in a murine model].

Xia LK, Zhang JS, Shu H.

Zhonghua Yan Ke Za Zhi. 2003 Mar;39(3):172-6. Chinese.

PMID:
12880576
20.

Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis.

Feitsma AL, van der Voort EI, Franken KL, el Bannoudi H, Elferink BG, Drijfhout JW, Huizinga TW, de Vries RR, Toes RE, Ioan-Facsinay A.

Arthritis Rheum. 2010 Jan;62(1):117-25. doi: 10.1002/art.25059.

Items per page

Supplemental Content

Write to the Help Desk